| News
Kybora settles its European headquarters in Basel
18.03.2021
The American consultancy Kybora, which operates within the life sciences industry, has established its European headquarters in Basel. Kybora GmbH will offer its services to European pharmaceutical companies from its location in Basel.

Kybora, a consulting firm based in the USA, is continuing its growth course from Basel, where it has founded Kybora GmbH and established its European headquarters according to a press release. Kybora aims to use this location to provide European life sciences companies with services in the areas of mergers and acquisitions, licensing, capital procurement, and strategic consulting.
Alan Vanderborght, Founder and CEO of Kybora, is quoted in the press release, saying: “Basel is the ideal location for our European headquarter.” He adds that the city has a “renowned pharma environment and a vibrant biotech industry” and is an ideal location right next to France and Germany, giving them “access to some of the brightest talents in these sectors”. Basel Area Business & Innovation, the location promotion and innovation support agency, helped Kybora during the relocation process.
Jean Chatellier will lead Kybora’s new European headquarters as Managing Director. He can rely on two decades of professional experience and pre-existing customers that will now be looked after from the Basel site. He further plans to arrange new, long-term partnerships with companies in Basel and across Europe.
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
KUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...
Read MoreCell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...
Read MoreBLKB expanding support for startups
BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...
Read MoreCombatting the rise of antimicrobial resistance
Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...
Read MoreAMR Action Fund invests in new antibiotics developed by BioVersys
The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...
Read MoreInvestors give Resistell 8.5 million Swiss francs
Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...
Read More